Hydroxyurea in old patients with essential thrombocythemia.

Area of Science:

• Hematology
• Oncology
• Clinical Medicine

Background:

• Advanced age and prior thrombosis are risk factors for thrombosis in essential thrombocythemia (ET).
• Cytotoxic drugs are typically used to reduce platelet counts in high-risk ET patients.
• Few studies specifically address treatment strategies for elderly ET patients, with some opting against platelet-reducing drugs.

Purpose of the Study:

• To compare the clinical outcomes of elderly ET patients treated with hydroxyurea (HU) versus those not receiving cytotoxic drugs.
• To evaluate the incidence of thrombosis and thrombosis-free survival in these patient groups.
• To assess the role of V617FJak2 mutation in thrombotic risk in elderly ET patients.

Main Methods:

• A retrospective, single-center study of 54 elderly ET patients with long follow-ups.
• Comparison of 27 patients not on cytotoxic drugs (Group A) with 27 patients on HU (Group B).
• V617FJak2 mutation analysis in a subset of patients; assessment of major side effects from HU.

Main Results:

• No significant difference in thrombosis incidence between the HU group and the no-drug group.
• V617FJak2 mutation prevalence was similar in both groups and did not correlate with thrombosis.
• Approximately 20% of HU-treated patients experienced major side effects.

Conclusions:

• The study, though limited by sample size and design, suggests HU may not offer significant thrombotic benefit in elderly ET patients.
• Hydroxyurea's side effect profile in the elderly warrants careful consideration, potentially leading to treatment discontinuation.
• V617FJak2 mutation status does not appear to predict thrombotic risk in this elderly ET population.